ABEONA THERAPEUTICS INC. Logo

ABEONA THERAPEUTICS INC.

Developing AAV-based cell and gene therapies for serious and rare diseases.

ABEO | US

Overview

Corporate Details

ISIN(s):
US00289Y2063
LEI:
Country:
United States of America
Address:
6555 CARNEGIE AVE, 4TH FLOOR, 44103 CLEVELAND
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for serious and rare diseases. The company's pipeline targets conditions with high unmet medical needs, including ophthalmic diseases like X-Linked Retinoschisis and Stargardt Disease, as well as Sanfilippo Syndrome and Infantile Batten Disease. Abeona develops adeno-associated virus (AAV)-based therapies and supports its programs through its in-house manufacturing facility, The Elisa Linton Center for Rare Disease Therapies. The company collaborates with partners such as Ultragenyx Pharmaceutical and Taysha Gene Therapies to advance its clinical development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ABEONA THERAPEUTICS INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ABEONA THERAPEUTICS INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ABEONA THERAPEUTICS INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM
Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA

Talk to a Data Expert

Have a question? We'll get back to you promptly.